

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from this translation.



November 14, 2025

Consolidated Financial Results for the Three Months Ended September 30, 2025 (Under Japanese GAAP)

Company name: Asahi Intecc Co., Ltd.
 Listing: Tokyo Stock Exchange and Nagoya Stock Exchange
 Securities code: 7747
 URL: <https://www.asahi-intecc.co.jp/>
 Representative: Kenji Miyata, President & CEO
 Inquiries: Mizuho Ito, Member of Board & CFO, General Manager of Administration
 Telephone: +81-561-56-1851
 Scheduled date of commencing dividend payments: –
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended September 30, 2025 (from July 1, 2025 to September 30, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
September 30, 2025	36,058	15.6	13,035	34.0	12,887	47.0	9,205	35.7
September 30, 2024	31,184	8.6	9,726	20.9	8,767	7.3	6,784	11.7

Note: Comprehensive income For the three months ended September 30, 2025: ¥11,795 million (360.6%)
 For the three months ended September 30, 2024: ¥2,560 million (-62.9%)

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
September 30, 2025	34.37	—
September 30, 2024	24.98	—

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Million yen	Million yen	%
September 30, 2025	184,846	148,941	80.1
June 30, 2025	193,187	151,354	77.9

Reference: Equity
 As of September 30, 2025: ¥148,119 million
 As of June 30, 2025: ¥150,558 million

2. Dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
Fiscal year ended June 30, 2025	Yen —	Yen —	Yen —	Yen 24.23	Yen 24.23
Fiscal year ending June 30, 2026	—				
Fiscal year ending June 30, 2026 (Forecast)		0.00	—	30.91	30.91

Note: Revisions to dividend forecasts announced most recently: None

3. Consolidated financial results forecast for the fiscal year ending June 30, 2026 (July 1, 2025 to June 30, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	130,870	9.0	32,642	8.5	32,809	11.0	23,811	86.9	88.30

Note: Revisions to financial results forecast announced most recently: None

*** Notes**

(1) Significant changes in scope of consolidation during the period: None

Newly included: -

Excluded: -

(2) Accounting treatments adopted specially for the preparation of quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common stock)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of September 30, 2025	271,633,600 shares
As of June 30, 2025	271,633,600 shares

(ii) Number of treasury shares at the end of the period

As of September 30, 2025	5,102,477 shares
As of June 30, 2025	1,964,677 shares

(iii) Average number of shares during the period (cumulative)

Three months ended September 30, 2025	267,814,831 shares
Three months ended September 30, 2024	271,625,637 shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

* Proper use of earnings forecasts, and other special matters

Financial results forecasts and other forward-looking statements provided in these materials are based on information available to the Company and certain other assumptions deemed reasonable as of the date of publication of this document, and do not represent any guarantee that the Company will achieve these results. Actual financial results and other aspects of business performance may differ significantly from these forecasts owing to various factors. Please refer to “1. Qualitative information on results for the quarter under review (3) Explanation of forecasts including consolidated results forecast” on page 3 of the attached materials for conditions forming the basis for financial results forecasts, notes regarding the use of financial results forecasts, and other information.

Table of contents of the attached materials

1. Qualitative information on results for the quarter under review	2
(1) Explanation of operating results	2
(2) Explanation of financial position	3
(3) Explanation of forecasts including consolidated results forecast	3
2. Quarterly consolidated financial statements and major notes	4
(1) Quarterly consolidated balance sheet	4
(2) Quarterly consolidated statements of income and comprehensive income	6
(3) Notes to quarterly consolidated financial statements	8
(Note on entity's ability to continue as going concern)	8
(Notes in the case of significant changes in amount of shareholders' equity)	8
(Notes on change in scope of consolidation or scope of application of equity method)	8
(Segment Information, etc.)	8
(Note to statement of cash flows)	9
(Revenue recognition)	10
(Significant subsequent events)	11

1. Qualitative information on results for the quarter under review

(1) Explanation of operating results

In the fiscal year ending June 30, 2026, the Asahi Intecc Group (the Group) aims to maintain a high level of growth and further enhance its corporate value by steadily promoting the growth strategies set forth in its new medium-term management plan, “Building the Future 2030,” which begins in the fiscal year ending June 30, 2026.

The Group’s performance for the three months ended September 30, 2025 progressed favorably, as follows.

Net sales amounted to 36,058 million yen (an increase of 15.6% year on year), driven by the strong performance of both the Medical and Device Divisions.

Gross profit totaled 25,436 million yen (an increase of 18.1% year on year), due to the increase in net sales and improvement in the gross profit margin in line with productivity improvements.

Operating profit was 13,035 million yen (an increase of 34.0% year on year), despite an increase in selling, general and administrative expenses, such as an increase in sales-related expenses aimed at strengthening sales in the U.S., as well as an increase in R&D expenses.

Ordinary profit was 12,887 million yen (an increase of 47.0% year on year), due to a decrease in foreign exchange losses.

Profit attributable to owners of parent was 9,205 million yen (an increase of 35.7% year on year), despite a decrease in reversal of allowance for doubtful accounts recorded as extraordinary income.

Foreign exchange rates used for the three months ended September 30, 2025:

147.45 yen per U.S. dollar (149.63 yen for the same period of the previous fiscal year, down 1.5%)

172.28 yen per euro (164.22 yen for the same period of the previous fiscal year, up 4.9%)

20.60 yen per Chinese yuan (20.84 yen for the same period of the previous fiscal year, down 1.2%)

4.56 yen per Thai baht (4.29 yen for the same period of the previous fiscal year, up 6.3%)

The operating results for each segment are outlined below.

<Medical Division>

In the Medical Division, net sales increased in all regions, both in Japan and overseas.

In the domestic market, net sales increased mainly due to strong performance of purchased peripheral vascular products in the non-cardiovascular field.

In the overseas market, net sales increased in both the cardiovascular and non-cardiovascular fields. In the cardiovascular field, net sales increased primarily for PCI guide wires in all regions. Although an increase in the Europe region partially includes front-loaded orders from distributors, performance was strong even excluding these transactions.

In the non-cardiovascular field, although sales of abdominal and neurovascular products decreased in the Chinese market, net sales increased overall due to strong sales of abdominal and peripheral vascular products in the U.S., Europe, and Asia.

As a result, net sales totaled 31,669 million yen (an increase of 12.3% year on year).

Segment profit amounted to 12,504 million yen (an increase of 22.7% year on year).

<Device Division>

In the Device Division, net sales increased in both medical and industrial components.

In addition, from the three months ended September 30, 2025, Nitta Mold was included in the scope of consolidation as a consolidated subsidiary, and the company’s profit and loss were reflected in the Group’s consolidated results.

As for medical components, net sales increased mainly due to an increase in transactions in cardiovascular inspection catheter components for U.S. companies and the consolidation of Nitta Mold as a subsidiary.

As for industrial components, net sales increased mainly due to an increase in leisure-related transactions in the overseas market and the consolidation of Nitta Mold as a subsidiary.

As a result, net sales totaled 4,389 million yen (an increase of 47.4% year on year).

Segment profit amounted to 2,471 million yen (an increase of 82.9% year on year), mainly due to an

increase in revenues from external customers.

(2) Explanation of financial position

As of September 30, 2025, total assets amounted to 184,846 million yen, a decrease of 8,341 million yen from the end of the previous fiscal year. This was mainly due to a decrease of 10,981 million yen in cash and deposits, despite an increase of 1,950 million yen in notes and accounts receivable – trade.

As for liabilities, total liabilities amounted to 35,905 million yen, a decrease of 5,928 million yen from the end of the previous fiscal year. This was mainly due to a decrease of 1,923 million yen in income taxes payable and a decrease of 1,307 million yen in provision for bonuses.

As for net assets, total net assets amounted to 148,941 million yen, a decrease of 2,412 million yen from the end of the previous fiscal year. This was mainly due to 7,703 million yen spent to purchase treasury shares, despite an increase of 2,697 million yen in retained earnings and an increase of 2,189 million yen in foreign currency translation adjustment.

(3) Explanation of forecasts including consolidated results forecast

In the three months ended September 30, 2025, performance progressed favorably, with both net sales and profit exceeding initial forecasts.

Net sales significantly exceeded expectations in the Europe region, mainly due to fluctuations owing to front-loaded orders from distributors. In Eastern Europe, which is part of the European region, the Group plans to implement price revisions through price increases from the second quarter in order to correct violative inflows to other regions. However, as these revisions may lead to a decline in net sales mainly in the second half of the fiscal year, the impact is currently under review. Although such temporary fluctuations unique to the European market exist, the Medical and Device Divisions, excluding Europe, have generally performed well. In addition, foreign exchange trends (yen depreciation) are also expected to have a positive impact, and overall performance is expected to remain steady.

The gross profit margin has been above the initially expected level, reflecting factors such as the increase in net sales and productivity improvements, although it may fluctuate depending on future sales trends.

Selling, general and administrative expenses have remained unspent for the three months ended September 30, 2025, but are expected to progress as planned for the full fiscal year.

As described above, since there are still uncertain factors such as sales trends, the full-year results forecast is currently under review. Accordingly, the financial results forecast announced on August 14, 2025, remains unchanged.

2. Quarterly consolidated financial statements and major notes

(1) Quarterly consolidated balance sheet

	(Million yen)	
	Previous consolidated fiscal year (June 30, 2025)	Three months under review (September 30, 2025)
Assets		
Current assets		
Cash and deposits	54,200	43,219
Notes and accounts receivable - trade	15,767	17,717
Electronically recorded monetary claims - operating	2,026	2,071
Merchandise and finished goods	9,408	9,443
Work in process	8,785	9,148
Raw materials and supplies	6,458	6,561
Other	7,004	6,089
Allowance for doubtful accounts	-291	-292
Total current assets	103,359	93,958
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	32,523	34,280
Other, net	26,559	25,847
Total property, plant and equipment	59,082	60,128
Intangible assets		
Goodwill	110	85
Other	5,485	5,377
Total intangible assets	5,595	5,462
Investments and other assets	25,149	25,296
Total non-current assets	89,827	90,887
Total assets	193,187	184,846

(Million yen)

	Previous consolidated fiscal year (June 30, 2025)	Three months under review (September 30, 2025)
Liabilities		
Current liabilities		
Notes and accounts payable – trade	2,655	3,048
Electronically recorded obligations - operating	424	587
Short-term borrowings	2,387	2,386
Income taxes payable	4,789	2,866
Provision for bonuses	2,868	1,561
Other	14,730	10,583
Total current liabilities	27,856	21,032
Non-current liabilities		
Long-term borrowings	6,633	6,038
Provision for retirement benefits for directors (and other officers)	19	19
Retirement benefit liability	2,943	3,118
Asset retirement obligations	197	198
Other	4,182	5,497
Total non-current liabilities	13,976	14,872
Total liabilities	41,833	35,905
Net assets		
Shareholders' equity		
Share capital	18,860	18,860
Capital surplus	21,779	21,779
Retained earnings	97,947	100,645
Treasury shares	-4,453	-12,157
Total shareholders' equity	134,134	129,128
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	2,008	2,402
Foreign currency translation adjustment	14,315	16,505
Remeasurements of defined benefit plans	99	82
Total accumulated other comprehensive income	16,424	18,990
Non-controlling interests	795	822
Total net assets	151,354	148,941
Total liabilities and net assets	193,187	184,846

(2) Quarterly consolidated statements of income and comprehensive income
Quarterly consolidated statement of income
For the three months ended September 30

(Million yen)

	Previous three months period (from July 1, 2024 to September 30, 2024)	Three months under review (from July 1, 2025 to September 30, 2025)
Net sales	31,184	36,058
Cost of sales	9,654	10,621
Gross profit	21,529	25,436
Selling, general and administrative expenses	11,803	12,401
Operating profit	9,726	13,035
Non-operating income		
Interest income	25	39
Dividend income	3	4
Subsidy income	93	74
Other	83	46
Total non-operating income	205	164
Non-operating expenses		
Interest expenses	144	39
Foreign exchange losses	927	185
Other	92	87
Total non-operating expenses	1,164	312
Ordinary profit	8,767	12,887
Extraordinary income		
Gain on sale of investment securities	23	—
Reversal of allowance for doubtful accounts	100	—
Total extraordinary income	123	—
Extraordinary losses		
Loss on sale of investment securities	—	6
Total extraordinary losses	—	6
Profit before income taxes	8,891	12,881
Income taxes - current	1,950	2,375
Income taxes - deferred	142	1,277
Total income taxes	2,092	3,652
Profit	6,798	9,228
Profit attributable to non-controlling interests	13	23
Profit attributable to owners of parent	6,784	9,205

Quarterly consolidated statement of comprehensive income
For the three months ended September 30

(Million yen)

	Previous three months period (from July 1, 2024 to September 30, 2024)	Three months under review (from July 1, 2025 to September 30, 2025)
Profit	6,798	9,228
Other comprehensive income		
Valuation difference on available-for-sale securities	-45	393
Foreign currency translation adjustment	-4,186	2,189
Remeasurements of defined benefit plans, net of tax	-5	-16
Total other comprehensive income	-4,237	2,566
Comprehensive income	2,560	11,795
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	2,557	11,768
Comprehensive income attributable to non-controlling interests	3	26

(3) Notes to quarterly consolidated financial statements
 (Note on entity's ability to continue as going concern)
 Not applicable.

(Notes in the case of significant changes in amount of shareholders' equity)

During the three months ended September 30, 2025, the Company acquired 3,137,800 shares of treasury shares based on the resolution of the Board of Directors' meeting held on May 15, 2025, resulting in an increase of 7,703 million yen in treasury shares.

As a result, the balance of treasury shares amounted to 12,157 million yen as of September 30, 2025.

(Notes on change in scope of consolidation or scope of application of equity method)

During the three months ended September 30, 2025, Nitta Mold Co., Ltd. and its subsidiary, NITTA M&T (THAILAND) CO., LTD., were included in the scope of consolidation.

(Segment Information, etc.)

[Segment Information]

I Three months ended September 30, 2024 (from July 1, 2024 to September 30, 2024)

1. Disclosure of sales and profit (loss) for each reportable segment

(Million yen)

	Reportable segment			Adjustments (Note 1)	Per quarterly consolidated financial statements (Note 2)
	Medical Division	Device Division	Total		
Net sales					
Revenues from external customers	28,205	2,978	31,184	—	31,184
Transactions with other segments	—	3,896	3,896	-3,896	—
Total	28,205	6,875	35,080	-3,896	31,184
Segment profit	10,190	1,351	11,541	-1,815	9,726

Notes: 1. The adjustment to segment profit includes corporate expenses that are not allocated to each reportable segment. Corporate expenses mainly consist of general and administrative expenses that do not belong to any reportable segment.
 2. Segment profit is adjusted with the operating profit in the quarterly consolidated statement of income.

II Three months ended September 30, 2025 (from July 1, 2025 to September 30, 2025)

1. Disclosure of sales and profit (loss) for each reportable segment

(Million yen)

	Reportable segment			Adjustments (Note 1)	Per quarterly consolidated financial statements (Note 2)
	Medical Division	Device Division	Total		
Net sales					
Revenues from external customers	31,669	4,389	36,058	—	36,058
Transactions with other segments	—	4,268	4,268	-4,268	—
Total	31,669	8,658	40,327	-4,268	36,058
Segment profit	12,504	2,471	14,976	-1,940	13,035

- Notes:
1. The adjustment to segment profit includes corporate expenses that are not allocated to each reportable segment. Corporate expenses mainly consist of general and administrative expenses that do not belong to any reportable segment.
 2. Segment profit is adjusted with the operating profit in the quarterly consolidated statement of income.

(Note to statement of cash flows)

The quarterly consolidated statement of cash flows for the three months ended September 30, 2025 has not been prepared.

Depreciation (including amortization of intangible assets excluding goodwill) and amortization of goodwill

	Previous three months period (from July 1, 2024 to September 30, 2024)	Three months under review (from July 1, 2025 to September 30, 2025)
Depreciation	2,337 million yen	2,195 million yen
Amortization of goodwill	309 million yen	28 million yen

(Revenue recognition)

Disaggregation of revenue from contracts with customers

(1) Breakdown by type

Three months ended September 30, 2024 (from July 1, 2024 to September 30, 2024)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Cardiovascular	21,546	–	21,546
Non-cardiovascular	4,658	–	4,658
OEM	2,001	–	2,001
Medical Components	–	1,941	1,941
Industrial Components	–	1,037	1,037
Total	28,205	2,978	31,184

Three months ended September 30, 2025 (from July 1, 2025 to September 30, 2025)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Cardiovascular	24,245	–	24,245
Non-cardiovascular	5,276	–	5,276
OEM	2,146	–	2,146
Medical Components	–	2,785	2,785
Industrial Components	–	1,603	1,603
Total	31,669	4,389	36,058

(2) Breakdown by region

Three months ended September 30, 2024 (from July 1, 2024 to September 30, 2024)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Japan	3,762	721	4,483
North America	5,445	942	6,388
Europe	5,716	122	5,839
China	9,303	128	9,431
Others	3,978	1,063	5,041
Total	28,205	2,978	31,184

Three months ended September 30, 2025 (from July 1, 2025 to September 30, 2025)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Japan	4,012	951	4,963
North America	6,016	1,420	7,437
Europe	7,608	156	7,765
China	9,598	202	9,800
Others	4,433	1,657	6,091
Total	31,669	4,389	36,058

(Significant subsequent events)

(Acquisition and cancellation of treasury shares)

The Company has resolved at the Board of Directors' meeting held on May 15, 2025 matters related to the acquisition of treasury shares pursuant to Article 156 of the Companies Act, as applied by replacing terms pursuant to Article 165, Paragraph 3 of the same Act, and completed the acquisition of 6,301,300 shares (common stock) on October 30, 2025.

In addition, at the Board of Directors' meeting held on the same day, the Company resolved, pursuant to Article 178 of the Companies Act, to cancel the treasury shares, and is scheduled to cancel the acquired 6,301,300 shares (representing 2.32% of the total number of issued shares) on November 28, 2025.